- Home
- / Silence Therapeutics
Silence Therapeutics
Stock Price
£5.6
2021-11-10
Market Capitalization
£497.1 M
2021-11-10
Revenue
$559 K
FY, 2025
Silence Therapeutics Summary
Company Summary
- Overview
- Silence Therapeutics is a therapeutics company that develops novel, proprietary short-interfering RNA.
- Type
- Public
- Status
- Active
- Founded
- 1999
- HQ
- London, GB | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Craig Tooman, President and Chief Executive Officer, Executive Director
James Ede-Golightly, Non-Executive Director
Alistair Gray, Senior Independent Non-Executive Director
LocationsView all
5 locations detected
London, England HQ
United Kingdom
72 Hammersmith Rd
Hoboken, NJ
United States
221 River St 9th floor
New York, NY
United States
434 W 33rd St #814
Berlin, Berlin
Germany
Robert-Rössle-Straße 10
London, England
United Kingdom
27 Eastcastle St, Fitzrovia
Silence Therapeutics Financials
Summary Financials
- Revenue (FY, 2025)
- $559.0K
- Gross profit (FY, 2025)
- $344.0K
- Net income (FY, 2025)
- ($88.6M)
- Cash (FY, 2025)
- $11.3M
- EBIT (FY, 2025)
- ($83.6M)
- Enterprise value
- $485.9M